A patent review of oxytocin receptor antagonists 2013-2017

References

• Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371(9608):261–269.
   PubMed Web of Science ®Google Scholar
• Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? where? why? Lancet. 2005;365(9462):891–900.
   PubMed Web of Science ®Google Scholar
• Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med. 1998;339(5):313–320.
   PubMed Web of Science ®Google Scholar
• Yaju Y, Nakayama T. Effectiveness and safety of ritodrine hydrochloride for the treatment of preterm labour: a systematic review. Pharmacoepidemiol Drug Saf. 2006;15(11):813–822.
   PubMed Web of Science ®Google Scholar
• Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Am J Obstet Gynecol. 2011;4(2):60–72.
   Google Scholar
• van Zijl MD, Bouchra Koullali BW, Mol J, et al. Prevention of preterm delivery: current challenges and future prospects. Int J Womens Health. 2016;8:633–645.
   PubMed Web of Science ®Google Scholar
• Read MD, Wellby DE. The use of a calcium antagonist (nifedipine) to suppress preterm labour. BJOG. 1986;93(9):933–937.
   Web of Science ®Google Scholar
• Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. Int J Gynaecol Obstet. 2005;91(1):10–14.
   PubMed Web of Science ®Google Scholar
• Moutquin J-M, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182(5):1191–1199.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–814.
   PubMed Web of Science ®Google Scholar
• Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res. 2005;17(1):39–57.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
   PubMed Web of Science ®Google Scholar
• McMahon C, Osterloh I, Rosen R, et al. Pd69-01 a phase IIa study to investigate the efficacy and safety of the selective oxytocin receptor antagonist, Ix-01, in men with lifelong premature ejaculation. J Urol. 2017;197(4):e1344.
   Web of Science ®Google Scholar
• Flouret G, Chaloin O, Borovickova L, et al. Design of novel bicyclic analogues derived from a potent oxytocin antagonist. J Pept Sci. 2006;12(6):412–419.
   PubMed Web of Science ®Google Scholar
• Liddle J. Glaxo Group Limited. Substituted diketopiperazines and their use as oxytocin antagonists. United States Patent US 8,071,594. 2011.
   Google Scholar
• Murphy Goodwin T, Millar L, North L, et al. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol. 1995;173(3):913–917.
   PubMed Web of Science ®Google Scholar
• Sparks MA, Freidinger RM, Perlow DS, et al. Merck & Co., Inc. Tocolytic oxytocin receptor antagonists. United States Patent 5,726,172. 1998.
   Google Scholar
• Vrachnis N, Malamas FM, Sifakis S, et al. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol. 2011;2011:1–8.
   Web of Science ®Google Scholar
• Williams PD, Bock MG, Evans BE, et al. Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency. Bioorg Med Chem Lett. 1999;9(9):1311–1316.
   PubMed Web of Science ®Google Scholar
• Nilsson L, Reinheimer T, Steinwall M, et al. Fe 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG. 2003;110(11):1025–1028.
   PubMed Web of Science ®Google Scholar
• Thornton S, Goodwin TM, Greisen G, et al. The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009;200(6):627.e1–627.e10.
   PubMed Web of Science ®Google Scholar
• Reinheimer TM. Barusiban suppresses oxytocin-induced preterm labour in non-human primates. BMC Pregn Childbirth. 2007;7(1):S15.
   PubMedGoogle Scholar
• Arce JC, Ferring BV. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies. United States Patent US 9579305. 2017..
   Google Scholar
• Chollet A, Obseva SA. Pyrrolidine derivatives as oxytocin/vasopressin 1a receptors antagonists. United States Patent Application 2015/0073032. 2015.
   Google Scholar
• Naylor AM, Russell RJ, Street SDA, et al. Treatment of male sexual dysfunction. United States Patent Application US 2015/0072995. 2015.
   Google Scholar
• Williams PD, Anderson PS, Ball RG, et al. 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]heptan-1(S)-Yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. J Med Chem. 1994;37(5):565–571.
   PubMed Web of Science ®Google Scholar
• Brown AD, Calabrese AA, Ellis D. Ixchelsis Limited. Substituted triazole derivatives as oxytocin antagonists. United States Patent Application US 2017/0114040. 2017.
   Google Scholar
• Brown AT, Brown B, Calabrese A, et al. Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent. Bioorg Med Chem Lett. 2010;20(2):516–520.
   PubMed Web of Science ®Google Scholar
• Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683.
   PubMed Web of Science ®Google Scholar